Sep 23 |
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
|
Jul 31 |
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
|
Jul 24 |
Alterity Therapeutics to Present at MST Financial Webinar
|
Jul 18 |
Alterity (ATHE) Up on Interim Data From Advance MSA Study
|
Jun 12 |
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
|
May 29 |
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
|
May 8 |
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
|
Apr 30 |
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
|
Apr 29 |
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
|
Apr 17 |
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
|